Ligand Pharmaceuticals Inc
LGND200.330USD
+1.920+0.97%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
3.94BMarket Cap
83.64P/E TTM
More Details of Ligand Pharmaceuticals Inc Company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Ligand Pharmaceuticals Inc Info
Ticker SymbolLGND
Company nameLigand Pharmaceuticals Inc
IPO dateNov 18, 1992
CEODavis (Todd C)
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 18
Address555 Heritage Drive, Suite 200
CityJUPITER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33458
Phone18585507500
Websitehttps://www.ligand.com/
Ticker SymbolLGND
IPO dateNov 18, 1992
CEODavis (Todd C)
Company Executives of Ligand Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
129.19K
+1.60%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
42.97K
-1.08%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
--
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
8.26K
-18.40%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+21.40%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.17K
-2.68%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
129.19K
+1.60%
Dr. John W. Kozarich ,Ph.D.
Dr. John W. Kozarich ,Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
42.97K
-1.08%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+3.57%
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
31.98K
--
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-7.77%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Other
12.64M
26.54%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Kyprolis
8.80M
18.48%
Captisol
8.29M
17.40%
Filspari
6.58M
13.81%
Qarziba
5.88M
12.36%
Royalties Other
5.43M
11.41%
Other
12.64M
26.54%
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.35%
The Vanguard Group, Inc.
10.53%
Janus Henderson Investors
5.30%
Nomura Investment Management Business Trust
3.82%
State Street Investment Management (US)
3.81%
Other
63.21%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.35%
The Vanguard Group, Inc.
10.53%
Janus Henderson Investors
5.30%
Nomura Investment Management Business Trust
3.82%
State Street Investment Management (US)
3.81%
Other
63.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
59.79%
Investment Advisor/Hedge Fund
39.05%
Research Firm
3.68%
Individual Investor
2.27%
Pension Fund
1.68%
Bank and Trust
1.63%
Hedge Fund
0.72%
Sovereign Wealth Fund
0.10%
Venture Capital
0.04%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
541
20.07M
102.40%
-232.93K
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
2023Q2
526
17.09M
98.94%
-1.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.65M
13.55%
-19.35K
-0.72%
Jun 30, 2025
The Vanguard Group, Inc.
2.08M
10.64%
+33.19K
+1.62%
Jun 30, 2025
Janus Henderson Investors
1.06M
5.41%
+33.19K
+3.23%
Jun 30, 2025
Nomura Investment Management Business Trust
926.55K
4.73%
+20.33K
+2.24%
Jun 30, 2025
State Street Investment Management (US)
749.75K
3.83%
+22.63K
+3.11%
Jun 30, 2025
Congress Asset Management Company, LLP
647.94K
3.31%
+5.23K
+0.81%
Jun 30, 2025
Chicago Capital, LLC
571.83K
2.92%
+17.31K
+3.12%
Jun 30, 2025
Stephens Investment Management Group, LLC
604.81K
3.09%
-2.41K
-0.40%
Jun 30, 2025
MFS Investment Management
339.74K
1.73%
+61.95K
+22.30%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
704.52K
3.6%
-40.41K
-5.42%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
4.21%
Invesco Pharmaceuticals ETF
3.2%
State Street SPDR S&P Pharmaceuticals ETF
3.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.74%
Virtus LifeSci Biotech Products ETF
2.67%
Invesco S&P SmallCap Health Care ETF
2.3%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
1.64%
iShares U.S. Pharmaceuticals ETF
1.38%
First Trust Multi-Manager Small Cap Opportunities ETF
1.09%
View more
Franklin Genomic Advancements ETF
Proportion4.21%
Invesco Pharmaceuticals ETF
Proportion3.2%
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.74%
Virtus LifeSci Biotech Products ETF
Proportion2.67%
Invesco S&P SmallCap Health Care ETF
Proportion2.3%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.64%
iShares U.S. Pharmaceuticals ETF
Proportion1.38%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion1.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ligand Pharmaceuticals Inc?
The top five shareholders of Ligand Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A. holds 2.65M shares, accounting for 13.55% of the total shares.
The Vanguard Group, Inc. holds 2.08M shares, accounting for 10.64% of the total shares.
Janus Henderson Investors holds 1.06M shares, accounting for 5.41% of the total shares.
Nomura Investment Management Business Trust holds 926.55K shares, accounting for 4.73% of the total shares.
State Street Investment Management (US) holds 749.75K shares, accounting for 3.83% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.65M shares, accounting for 13.55% of the total shares.
The Vanguard Group, Inc. holds 2.08M shares, accounting for 10.64% of the total shares.
Janus Henderson Investors holds 1.06M shares, accounting for 5.41% of the total shares.
Nomura Investment Management Business Trust holds 926.55K shares, accounting for 4.73% of the total shares.
State Street Investment Management (US) holds 749.75K shares, accounting for 3.83% of the total shares.
What are the top three shareholder types of Ligand Pharmaceuticals Inc?
The top three shareholder types of Ligand Pharmaceuticals Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Janus Henderson Investors
How many institutions hold shares of Ligand Pharmaceuticals Inc (LGND)?
As of 2025Q3, 541 institutions hold shares of Ligand Pharmaceuticals Inc, with a combined market value of approximately 20.07M, accounting for 102.40% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.27%.
What is the biggest source of revenue for Ligand Pharmaceuticals Inc?
In FY2025Q2, the Kyprolis business generated the highest revenue for Ligand Pharmaceuticals Inc, amounting to 8.80M and accounting for 18.48% of total revenue.
